The F-MACHOP sequential combination chemotherapy regimen in advanced diffuse aggressive lymphomas: Long-term results
- 1 May 1991
- journal article
- clinical trial
- Published by Elsevier in Annals of Oncology
- Vol. 2 (5) , 365-372
- https://doi.org/10.1093/oxfordjournals.annonc.a057958
Abstract
The present study reports the long-term results of the F-MACHOP sequential combination chemotherapy regimen in 113 adult patients with advanced stages of diffuse large-cell or undifferentiated lymphoma who were consecutively treated with this regimen from January 1980 to December 1986 at a single institution. The CR rate was 78% and 17 relapses were observed, so that 80% of CR patients are expected to be free of relapse at 5 and 10 years after a median follow-up off-therapy of 5.7 years (range 3.2–10.1). Projected survival and event-free survival at 8 years are 68% and 62%, respectively. Prognostic factor analysis indicates that the CR rate was influenced by systemic symptoms and number of extranodal sites, disease-free survival by tumor burden and number of courses to achievement of CR, event-free survival and survival by tumor mass diameter, systemic symptoms and number of extranodal sites. Toxicity was mainly hematological, and 3 patients (3%) died while severely neutropenic. The rapidity of response appears to have prognostic value, particularly in patients presenting with high tumor burden, in whom achievement of a CR within 3 courses indicates a group of patients with a very high chance of cure with this regimen.Keywords
This publication has 15 references indexed in Scilit:
- The m-BACOD combination chemotherapy regimen in large-cell lymphoma: analysis of the completed trial and comparison with the M-BACOD regimen.Journal of Clinical Oncology, 1990
- Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: significance and management.Journal of Clinical Oncology, 1988
- Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP)Blood, 1988
- Sequential Combination Chemotherapy of High-Grade Non-Hodgkin's Lymphoma with 5-Fluorouracil, Methotrexate, Cytosine-Arabinoside, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (F-MACHOP)Cancer Investigation, 1987
- Identification of Major Prognostic Subgroups of Patients with Large-Cell Lymphoma Treated with m-BACOD or M-BACODAnnals of Internal Medicine, 1986
- Chemotherapy for diffuse large-cell lymphoma--rapidly responding patients have more durable remissions.Journal of Clinical Oncology, 1986
- National cancer institute sponsored study of classifications of non-hodgkin's lymphomas. Summary and description of a working formulation for clinical usageCancer, 1982
- Combination chemotherapy of diffuse histiocytic lymphoma with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP)Cancer, 1978
- ADVANCED DIFFUSE HISTIOCYTIC LYMPHOMA, A POTENTIALLY CURABLE DISEASEThe Lancet, 1975
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958